Agendia Opens CLIA-Registered U.S. Genomics Laboratory

HUNTINGTON BEACH, California and AMSTERDAM, May 26 /PRNewswire/ –
Agendia, a world leader in molecular cancer diagnostics, today announced the
opening of its U.S. clinical genomics laboratory in Huntington Beach, CA. The
laboratory is fully-licensed and compliant with the Clinical Laboratory
Improvements Amendments (CLIA) as administered by the Centers for Medicare
and Medicaid Services (CMS).

In addition to opening its U.S. cancer genomics laboratory, Agendia has
over the past months made several key additions to its domestic-based senior
executive team. The team consists of Dr. Richard Bender, Chief Medical
Officer, Mr. Daniel Forche, Vice President of Sales & Marketing, Mr. Alan B.
Carter, Vice President of Global Business Development, and pathologist Dr.

“Our new genomics lab’s capacity will allow us to meet the increasing
demand for MammaPrint across the United States and give physicians and
patients optimal test result turnaround and unmatched service and support,”
noted Jan Groen, Ph.D., Chief Operating Officer. “This expansion places us in
an excellent position to continue making advancements in molecular cancer
diagnostics and equip oncologists with powerful tools to use in the fight
against breast cancer.”

Dr. Bernhard Sixt, President and Chief Executive Officer, added, “the
opening of the Huntington Beach laboratory and the appointment of our
U.S.-based commercial team provide a strong basis for our U.S. operations and
for Agendia’s next phase of growth. Our enhanced domestic capabilities will
help us to further drive adoption of MammaPrint, and place us in an even
better position to collaborate with a growing number of clinical, academic,
and industrial partners here in the U.S.”

Dr. Bender has more than 30 years of medical and professional experience
as a practicing oncologist and director of several oncology programs. Dr.
Bender has served as Medical Director of the Hematology/Oncology Program at
Quest Diagnostics, Director of Medical Oncology and Hematology at Kaiser
Permanente Medical Group, Director of Strategic Development in Medical
Oncology/Hematology at Johnson & Johnson, and as an investigator at the
National Cancer Institute and Scripps Clinic and Research Foundation.
Currently, Dr. Bender serves as an expert reviewer in oncology for the
Medical Board of California, co-Editor of Anti-Cancer Drugs, an international
journal on anti-cancer agents, and as a clinical instructor in medicine at
the University of California, Irvine School of Medicine.

Mr. Forche brings more than 18 years of sales, marketing and commercial
leadership experience in the diagnostics arena. Prior to joining Agendia, Mr.
Forche was the Senior Vice President of Sales and Marketing for Insight
Health Corporation, a national leader in diagnostic imaging services. He also
served as Vice President of Marketing at US LABS, an industry leader in
cancer diagnostic and genomic testing services, and has held sales and
marketing management roles at Ventana Medical Systems (now Roche) and Abbott
Laboratories.

Mr. Carter joins Agendia with 25 years of global business development
experience from a number of top-tier life sciences companies such as
BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he
oversees ongoing strategic alliances within the bio-pharmaceutical sector and
collaboration with partners interested in Agendia’s expanding molecular
diagnostics portfolio.

Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with more than 30
years of experience as a laboratory director. He is currently also Director
of National Cyto-Path Laboratories and Professional Pathology Medical Group
Laboratory, both in Long Beach, California; and Director of the Laboratory
and Department of Pathology at the Miracle Mile Medical Center, Los Angeles.
Dr. Henning is a Fellow of the American Society of Clinical Pathologists and
the College of American Pathologists.

Ongoing research and development commitments continue to augment
Agendia’s ability to accurately predict breast cancer recurrence and
sub-typing, and help physicians tailor individual treatment plans to their
patients. Agendia’s goal is to provide women with answers to crucial
treatment questions, such as how their breast cancer will respond to targeted
therapies or various chemotherapy regimens.

For more information, please visit http://www.agendia.com

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatment within reach of
patients. Building on a cutting edge genomics platform for tumor gene
expression profiling, the company’s tests aim to help physicians more
accurately tailor cancer therapy. The company markets four products, with
several new genomic tests in development. Agendia collaborates with
pharmaceutical companies in the development of highly effective personalized
drugs in the area of oncology. Agendia was awarded the 2008 North American
Oncology Clinical Diagnostics Healthcare Innovation Award by Frost &
Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam,
The Netherlands. For more information please visit http://www.agendia.com.

SOURCE Agendia B.V.